Abstract
Although asthma is a common respiratory condition, there is no standardised definition of the type, severity or frequency of symptoms, nor of the findings on investigation. Therefore, it is not possible to make evidence-based recommendations on how to diagnose patients with asthma. This article describes the use of the fraction of exhaled nitric oxide (FeNO) as a biomarker of airway inflammation, thereby assisting diagnosis of asthma in clinical practice. FeNO can also be used to monitor adherence to inhaled corticosteroid therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
